The use of gonadotropin‐releasing hormone agonist (GnRHa) as part of treatment to prevent chemotherapy‐induced premature ovarian failure has been studied in particular in breast cancer patients, and has been shown to reduce the risk regardless of hormone receptor status.26 This evidence concerns the gene NR4A1 and primary ovarian failure.